ArticleCost effectiveness and resource allocation : C/E2023

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.

Dolores Isla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.